Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AML patients give their own transfusions at home?

NCT ID NCT07062250

Symptom relief Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers at Rigshospitalet in Denmark are testing whether adults newly diagnosed with acute myeloid leukemia can safely measure their own blood counts and give themselves blood and platelet transfusions at home. The study trains and certifies 22 participants to use a home blood-count device, administer transfusions, and check blood pressure, pulse, oxygen, and temperature before and after each transfusion. The team tracks technical problems, transfusion reactions, unplanned hospital visits, and quality of life to see whether home care can replace some day-hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Home-based blood count measurement and self-administered blood and platelet transfusions
What this could lead to
If it works, patients with AML could spend fewer days at the hospital and manage some transfusion care at home, with fewer nurse visits needed.
What could go wrong
This is a small, single-arm feasibility study of 22 people, so it cannot prove home transfusions are as safe as hospital ones. Patients must be able to learn the technique, and serious transfusion reactions or device errors remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

22 people

The number who actually took part.

Started

Apr 2024

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 18 years old * newly diagnosed with AML within four weeks * scheduled to receive home-based chemotherapy. Exclusion Criteria: * Patients who do not understand or speak Danish * Incapable of performing home-based CBC measurements and administration of transfusions. * Patients will be discontinued if they do not achieve remission after the second chemotherapy cycle.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukaemia (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia Patient Participation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukaemia (AML)

Contacts and locations

Locations

  • Rigshospitalet

    Copenhagen, Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.